Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CDA | P32320 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909059 | 0.88 | TMEM97 (0.47) | MAPTCDASLC5A2SLC28A1SLC28A2 | |
| SCHEMBL6906785 | 0.83 | ADK (0.41) | ADK | |
| SCHEMBL27784868 | 0.82 | MAPT (0.42) | MAPTCDASLC5A2SLC28A1SLC28A2 | |
| SCHEMBL9711039 | 0.81 | SLC5A2 (0.44) | MAPTCDASLC5A2 | |
| SCHEMBL6908967 | 0.80 | TK2 (0.44) | MAPTCDASLC5A2SLC28A1SLC28A2 | |
| SCHEMBL16342011 | 0.74 | TYMP (0.40) | — | |
| SCHEMBL2913461 | 0.73 | TYMP (0.39) | SLC5A2 | |
| SCHEMBL9135382 | 0.73 | LGALS9 (0.38) | SLC5A2 | |
| SCHEMBL16340896 | 0.72 | TK2 (0.42) | — | |
| Netivudine SCHEMBL9538356 | 0.71 | PYGM (0.63) | MAPTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699690-B2 | LINKED AND CONTROLLING THE EXPRESSION OF A HETEROLOGOUS ENZYME, FOR EXAMPLE VARICELLA ZOSTER VIRUS THYMIDINE KINASE OR NON-MAMMALIAM CYTOSINE DEAMINASE | SMITHKLINE BEECHAM CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-20020055482-A1 | Linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase or non-mammaliam Cytosine Deaminase | SMITHKLINE BEECHAM CORPORATION | 2002-05-09 | — | — | US | disclosed |
| US-6337209-B1 | A CHIMERIC MOLECULE; THERAPY FOR COLORECTAL CANCER | GLAXO WELLCOME INC. | 2002-01-08 | — | — | US | disclosed |
| US-6300490-B1 | EXPRESSION VECTOR CODING CYTOSINE DEAMINASE; FOR USE IN THE TREATMENT OF CANCERS | GLAXO WELLCOME INC. | 2001-10-09 | — | — | US | disclosed |
| EP-0486477-A2 | 1-( -D-Arabinofuranosyl)-5-propynyluracil as a VZV-antiviral compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-20 | — | — | EP | disclosed |
| EP-0417560-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0272065-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055482-A1 | Linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase or non-mammaliam Cytosine Deaminase | TK1, CDA, DCTD | ADORA1 2491/4885MAPT 4480/4885CDA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.